ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   
 Top Breaking News
 Wednesday, July 23, 2014

ViiV Healthcare: HIV Combo Therapy Candidate Fails Phase 3

FDA Grants Genentech (RHHBY)’s Avastin Priority Review For Recurrent Platinum-Resistant Ovarian Cancer

SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus

Baxter International, Inc. (BAX) Initiates Voluntary Worldwide Recall Of Four Lots Of IV Solutions Due To The Presence Of Particulate Matter

Aduro Biotech Receives Breakthrough Therapy Designation From FDA For Innovative Pancreatic Cancer Combination Immunotherapy

Amgen (AMGN) Thyroid Drug AMG 416 Succeeds In Late Stage Kidney Patient Trial

Unique Pharmaceuticals, Ltd. Announces A Voluntary Nationwide Recall Of All Sterile Compounded Preparations Within Their Expiry Period Due To A Lack Of Sterility Assurance

InterMune, Inc. (ITMN) Grabs FDA Breakthough Therapy Designation For IPF Drug Pirfenidone

More News



 Yesterday's Most Popular News 
Baxter International, Inc. (BAX) Initiates Voluntary Worldwide Recall Of Four Lots Of IV Solutions Due To The Presence Of Particulate Matter

Aduro Biotech Receives Breakthrough Therapy Designation From FDA For Innovative Pancreatic Cancer Combination Immunotherapy

Avid Cyclists Could Have Higher Prostate Cancer Risk, University College London Study

Consuming Probiotics For A Month Helps Diminish Fat Accumulation In The Liver, University of Granada Study

Amgen (AMGN) Thyroid Drug AMG 416 Succeeds In Late Stage Kidney Patient Trial

Divorce Is More Common Among Families With Girls, Duke University Study

Women's Professional Self-Identity Impacts On Childcare Balance, But Not Men's, Cambridge University Study

Fish Oil May Benefit Alcohol Abusers, Loyola University Health System Study

Regulus Therapeutics, Inc. Receives Orphan Drug Designation For RG-012, A microRNA Therapeutic For The Treatment Of Alport Syndrome

Unique Pharmaceuticals, Ltd. Announces A Voluntary Nationwide Recall Of All Sterile Compounded Preparations Within Their Expiry Period Due To A Lack Of Sterility Assurance


 
-

 Featured Stories
 

  Today's Top Jobs

 Featured Employer
About Genzyme Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis. Learn more at www.jobsatgenzyme.com. Follow our jobs on Twitter www.twitter.com/genzymejobs. Follow us on LinkedIn http://www.linkedin.com/company/genzyme. About Sanofi Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Show me jobs for this employer

 Careers
 
More Career Tips